Venue suggestions

Venue Recommendations

as_is

Empty — the editor's verdict of "major" with 61/100 readiness indicates the manuscript requires substantial revision before it is suitable for peer-reviewed publication at any competitive venue.

---

after_revision

Nature Immunology or Immunity

• Fit: Both journals prioritize mechanistic immunology and stromal–immune crosstalk in chronic inflammation. The NOTCH3→neurotrophin→mural-cell axis is a novel stromal pathway; the spatial transcriptomics dataset is high-dimensional and well-executed; the translational angle (TRK inhibitors in RA) aligns with these venues' scope. The paper's core strength — tracing a signaling cascade across five independent methodologies — is exactly what these journals reward.
• Odds after revision: Moderate to good (40–55%). The required revisions are substantial but all addressable without new conceptual work. The remission-independence claim and absolute-density reanalysis will likely require either new data or careful restatement; if those are handled cleanly, the paper is competitive. The viability control for explants is a single short experiment and unlikely to be a barrier if negative (i.e., if TRK inhibition does not cause toxicity). The "differentiation" language fix is textual. Rejection risk remains if the absolute-count reanalysis reveals that mural-cell expansion is an artifact of denominator drift, but the panel's debate suggests this is unlikely given the selectivity of the effect.

Science Translational Medicine

• Fit: This venue explicitly values mechanistic discovery coupled to therapeutic actionability. The NOTCH3–neurotrophin pathway is mechanistically novel; the use of FDA-approved TRK inhibitors (larotrectinib, entrectinib) in human RA explants is directly translational; the framing as a "treatment-resistant disease compartment" is exactly the problem STM targets. The spatial transcriptomics and multi-method validation are appropriate for the venue's standards.
• Odds after revision: Moderate (35–50%). STM is more forgiving of incomplete mechanistic detail if the translational promise is clear and the evidence for efficacy in human tissue is solid. However, the viability control for explants becomes more critical here, not less, because the therapeutic claim is the headline. If TRK inhibition causes tissue toxicity, the paper must either show that de-maturation occurs before toxicity or pivot to a mechanistic-only framing. The absolute-density issue is less likely to be a barrier at STM if the selectivity argument holds.

Arthritis & Rheumatism (or Arthritis Research & Therapy)

• Fit: These are the primary venues for RA mechanistic work. The paper's focus on stromal remodeling and treatment resistance is directly on-topic. The spatial transcriptomics approach is state-of-the-art for synovial tissue analysis. The panel's verdict reflects sound science, not a mismatch with RA rheumatology.
• Odds after revision: Good to very good (55–70%). RA-focused journals are more tolerant of incomplete translational validation (e.g., explant-only data) and more interested in the mechanistic pathway itself. The required revisions are all standard for this venue. The main risk is if the absolute-density reanalysis substantially weakens the "persistence despite treatment" claim, but even a restatement to "maturation is not reversed by treatment" remains publishable and important.

---

alternative

bioRxiv (preprint server)

• Rationale: If the required revisions prove infeasible (e.g., if absolute-density reanalysis reveals the effect is an artifact, or if the viability control shows TRK inhibition is toxic), posting on bioRxiv preserves priority and allows the community to evaluate the mechanistic pathway independently of the translational claims. The spatial transcriptomics dataset and NOTCH3–neurotrophin tracing are valuable even if the treatment-resistance and drug-reversibility claims do not hold.
• Notes: This is a fallback only; the manuscript is currently suitable for preprint, but the required revisions are designed to make it suitable for peer review at a top-tier venue.

eLife

• Fit: eLife publishes high-quality mechanistic work across disciplines and is known for thorough but fair peer review. The paper's multi-method validation and spatial dataset would be well-received. eLife is also more flexible about incomplete translational data if the mechanism is well-traced.
• Odds after revision: Moderate (40–50%). eLife's bar for novelty and rigor is high, but the venue is less specialized in RA and may be less forgiving of incomplete clinical context (e.g., the remission-independence claim). The paper is competitive here if the required revisions are addressed cleanly, but it is a secondary choice compared to Immunity or Arthritis & Rheumatism.

Journal of Clinical Investigation (JCI)

• Fit: JCI values mechanistic discovery in disease contexts and is receptive to stromal biology and translational angles. The paper's scope and rigor are appropriate.
• Odds after revision: Moderate (35–45%). JCI's bar for novelty is high and the paper's core mechanism (NOTCH→neurotrophin→mural-cell fate) is incremental on existing NOTCH3 biology in vascular development, even if the RA context is new. The translational angle helps, but only if the viability control is clean. This is a reasonable secondary target if Immunity or STM decline.

---

Notes on Revision Strategy

1. The denominator issue (Required Revision 1) is the highest-stakes item. If absolute vascular counts do not increase post-treatment, the headline claim shifts from "pathological maturation persists and expands" to "maturation is not reversed." Both are interesting, but only the former justifies the current framing. Reanalyze this immediately; it will determine whether the paper is suitable for Nature Immunology (which demands novelty) versus Arthritis & Rheumatism (which is more forgiving of a negative or neutral result if the mechanism is solid).

2. The viability control (Required Revision 2) is the second-highest-stakes item for translational venues. If TRK inhibition does not cause toxicity in explants, the paper is competitive at STM and Nature Immunology. If it does, the paper remains mechanistically sound but the therapeutic framing must be dropped or heavily qualified, and STM becomes a poor fit. Do this experiment early.

3. The "differentiation" language (Required Revision 3) is a text fix, not a data problem. Recast to "induces mural-cell marker and contractile programs" and the concern evaporates. This is low-risk.

4. After addressing these three, the remaining revisions are compliance and completeness items (sample sizes, multiple-comparison correction, data deposition, citation fixes). They are essential for reproducibility and trust but are unlikely to change the editorial verdict if the three above are solid.

5. Do not attempt to add new experiments beyond the viability control and absolute-density reanalysis. The panel's debate suggests the mechanism is sound; additional data will not materially improve the odds and will delay submission. Focus on reanalysis and reframing.